These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4682751)

  • 1. L-dopa, dopamine, and hypomania.
    Murphy DL; Goodwin FK; Brodie HK; Bunney WE
    Am J Psychiatry; 1973 Jan; 130(1):79-82. PubMed ID: 4682751
    [No Abstract]   [Full Text] [Related]  

  • 2. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
    Goodwin FK; Murphy DL; Brodie HK; Bunney WE
    Biol Psychiatry; 1970 Oct; 2(4):341-66. PubMed ID: 4920729
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania.
    Bunney WE; Brodie HK; Murphy DL; Goodwin FK
    Am J Psychiatry; 1971 Jan; 127(7):872-81. PubMed ID: 4924778
    [No Abstract]   [Full Text] [Related]  

  • 4. Psychobiological and pharmacological studies of manic-depressive illness.
    Bunney WE; Gershon ES; Murphy DL; Goodwin FK
    J Psychiatr Res; 1972 Sep; 9(3):207-26. PubMed ID: 5083175
    [No Abstract]   [Full Text] [Related]  

  • 5. L-dopa, behavioral activation and psychopathology.
    Murphy DL
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():472-93. PubMed ID: 4627219
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 7. Regular induction of hypomania by L-dopa in "bipolar" manic-depressive patients.
    Murphy DL; Brodie HK; Goodwin FK; Bunney WE
    Nature; 1971 Jan; 229(5280):135-6. PubMed ID: 4321339
    [No Abstract]   [Full Text] [Related]  

  • 8. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 10. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of aminazine on the excretion of adrenaline noradrenaline, dopamine and dopa in healthy subjects and in the manic phase of manic-depressive psychosis].
    Matlina ESh; Osipova MS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(1):128-31. PubMed ID: 5448719
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
    Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
    Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral L-dopa treatment of parkinsonism.
    Andén NE; Carlsson A; Kerstell J; Magnusson T; Olsson R; Roos BE; Steen B; Steg G; Svanborg A; Thieme G; Werdinius B
    Acta Med Scand; 1970 Apr; 187(4):247-55. PubMed ID: 4911257
    [No Abstract]   [Full Text] [Related]  

  • 14. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 15. Behavioural and biochemical interaction between caffeine and L-dopa.
    Strömberg U; Waldeck B
    J Pharm Pharmacol; 1973 Apr; 25(4):302-8. PubMed ID: 4146682
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose-related alterations in metabolism of levodopa: possible mechanism for hypotensive effect.
    Kochar MS; Itskovitz HD; Sasse EA; Baker JD; Doumas BT
    J Clin Pharmacol; 1974; 14(8):448-54. PubMed ID: 4851433
    [No Abstract]   [Full Text] [Related]  

  • 17. [The influence of diethyldithiocarbamate on cerebral catecholamine, spontaneous activity and L-DOPA hyperactivity].
    Aigner A; Hornykiewicz O; Lisch HJ; Springer A
    Med Pharmacol Exp Int J Exp Med; 1967; 17(6):576-85. PubMed ID: 5631692
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of L-dopa and L-3-methoxytyrosine on D-methamphetamine-induced motor activity and seizures induced by electroshock.
    McLean JR; Ensor CR; McCarthy DA; Bohner B; Potoczak D
    Proc Soc Exp Biol Med; 1973 Sep; 143(4):1083-7. PubMed ID: 4743685
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolism of dihydroxyphenylalanine and tryptophan in pyridoxine-deficient rats.
    Sourkes TL; Missala K
    Ann N Y Acad Sci; 1969 Sep; 166(1):235-45. PubMed ID: 5262018
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.